US4289750A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapy of conditions which may be associated with altered renal function and dosage forms therefor
Assignee: Individual
•
Filing: 1979-10-15
•
Granted: 1981-09-15
•
Expires: 1999-10-15
Abstract
Abstract The invention concerns a method of treating a subject suffering from abnormal distribution and retention of body fluids such as may be the result of altered renal function, which comprises the step of administering to a subject in need of such treatment, a therapeutically effective amount of a pharmaceutically acceptable alkaline acting substance capable of increasing patient plasma bicarbonate level to a value in excess of that prior to treatment. Oral preparations, in particular an alkaline substance capable of releasing bicarbonate ions, for therapy of a large variety of ailments and diseases, are disclosed.
Inventors
- 👤 Klaus F. Kopp
- 👤 Joachim W. Helbig
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 02:46
CPC Classifications
A; A61; A61K; A61K33/00; A61K33/14
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
108 words
A method of treating a subject suffering from abnormal distribution and retention of body fluids and retention products which is as a result of altered renal function, which comprises orally administering to a subject in need of such treatment, a therapeutically effective amount of an oral dosage form of a pharmaceutically acceptable alkaline acting substance adapted to release sodium and bicarbonate ions in the small intestine of the subject and being capable of increasing patient plasma bicarbonate level to a value in excess of that prior to treatment, the therapeutically effective amount being sufficient to substantially correct metabolic acidosis and increase urine production and clearance of retention products.
Claim 2
Independent Claim
108 words
A method of treating a subject suffering from abnormal distribution and retention of body fluids and retention products which is as a result of altered renal function, which comprises orally administering to a subject in need of such treatment, a therapeutically effective amount of an oral dosage form of a pharmaceutically acceptable alkaline acting substance adapted to release sodium and bicarbonate ions in the small intestine of the subject and being capable of increasing patient plasma bicarbonate level to a value in excess of that prior to treatment, the therapeutically effective amount being sufficient to substantially correct metabolic acidosis and increase urine production and clearance of retention products.
Claim 3
Dependent Claim
35 words
A method according to claim 1, in which the therapeutically effective amount of the alkaline acting substance is estimated on the basis of the body weight of the subject and a determined plasma base deficit.
Claim 4
Dependent Claim
28 words
A method according to claim 1, in which the therapeutically effective amount of the alkaline acting substance is sufficient to establish a plasma base excess in the subject.
Claim 5
Dependent Claim
38 words
A method according to claim 1, in which the therapeutically effective amount of the alkaline acting substance is at least sufficient to lead to a detectable increase in fresh patient urine pH value over that prior to treatment.
Claim 6
Dependent Claim
27 words
A method according to claim 1, in which the patient plasma bicarbonate level is maintained at said increased value by intermittent administration of the alkaline acting substance.
Claim 7
Dependent Claim
44 words
A method according to claim 4, in which the fresh patient urine pH value is increased to said increased value each time the fresh patient urine pH value falls below said increased value, by further administration of an amount of the alkaline acting substance.
Claim 8
Dependent Claim
29 words
A method according to claim 1, in which the maintenance of said increased patient plasma bicarbonate level is determined by observing a maintained increased fresh patient urine pH value.
Claim 9
Dependent Claim
36 words
A method according to claim 1, in which the amount of alkaline acting substance administered to maintain said increased patient plasma bicarbonate level is sufficient to maintain fresh patient urine pH value in excess of 6.5.
Claim 10
Dependent Claim
28 words
A method according to claim 8, in which the amount of alkaline acting substance administered is sufficient to maintain fresh patient urine pH value between 6.8 and 8.
Claim 11
Dependent Claim
15 words
A method according to claim 1, in which the alkaline acting substance is sodium bicarbonate.
Claim 12
Dependent Claim
33 words
An oral dosage form of an alkaline active substance capable of increasing plasma bicarbonate level to a value in excess of that prior to treatment, for use in the method of claim 1.
Claim 13
Dependent Claim
17 words
An oral dosage form according to claim 11, comprising sodium bicarbonate enclosed within an acid-resistant alkali-decomposable enclosure.
Claim 14
Dependent Claim
21 words
An oral dosage form according to claim 12, in which the acid-resistant alkali-decomposable enclosure comprises a gastric juice resistant acrylic resin.
Claim 15
Dependent Claim
37 words
An oral dosage form according to claim 12, in which the acid-resistant alkali-decomposable enclosure is a capsule enclosure rendered resistant to gastric juice with the aid of a mixture of hydroxypropyl methyl cellulose phthalate and dibutyl phthalate.
Claim 16
Dependent Claim
45 words
An oral dosage form according to claim 11, in which the alkaline acting substance is associated with additional active agents, such as may be employed in the therapy of diseases and ailments which can be as a result of partial or temporarily altered renal function.
Claim 17
Dependent Claim
46 words
An oral dosage form according to claim 15, in which the additional active agents are selected from substances suitable for the prophylaxis and therapy of kidney stones, selected from the group consisting of an alkali metal or alkaline earth metal salt of citric acid, or urea.
Claim 18
Dependent Claim
25 words
An oral dosage form according to claim 15, in which the additional active agent is a calcium compound suitable for supplementing calcium in a subject.
Claim 19
Dependent Claim
16 words
An oral dosage form according to claim 17, in which the calcium compound is calcium gluconate.
Claim 20
Dependent Claim
25 words
An oral dosage form according to claim 15, in which the additional active agent is a potassium compound suitable for supplementing potassium in a subject.
Claim 21
Dependent Claim
25 words
An oral dosage form according to claim 19, in which the potassium compound is one or more of potassium chloride, potassium bicarbonate, and potassium citrate.
Claim 22
Dependent Claim
43 words
An oral dosage form according to claim 11, in unit dosage form, comprising from about 500 to about 1500 mg of sodium bicarbonate enclosed within an acid-resistant alkali-decomposable enclosure enabling release of sodium and bicarbonate ions in the small intestine of a subject.
Claim 23
Dependent Claim
28 words
An oral dosage form according to claim 15, in which trace elements recognised to contribute to the general well-being of patients are comprised in the oral dosage form.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-14 | 1985-03-16 | 1985-09-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-14 | 1989-03-16 | 1989-09-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-14 | 1993-03-16 | 1993-09-15 | $7700.00 | Window Closed / Lapsed |